Alkermes
Alkermes, Inc. is an integrated biotechnology company focused on developing, manufacturing, and commercializing medicines for chronic diseases. The company specializes in therapeutic areas such as central nervous system disorders, addiction, diabetes, and autoimmune disorders. Alkermes' key products include VIVITROL, an extended-release formulation of naltrexone used for treating alcohol dependence, and RISPERDAL CONSTA, an injectable medication for schizophrenia and bipolar I disorder. The company operates a research facility in Massachusetts and a commercial manufacturing facility in Ohio. Alkermes employs its proprietary technologies to create pharmaceutical products that address unmet medical needs, and it collaborates with third-party partners to enhance its product development efforts. With a significant presence in the United States, Alkermes also extends its operations to Ireland and other international markets.
17 past transactions
Mural Oncology
Corporate Round in 2023
Mural Oncology is an independent public company. Mural Oncology would focus on the discovery and development of cancer therapies, including the continued development of nemvaleukin alfa and the company's portfolio of novel, preclinical engineered cytokines, comprised of tumor-targeted split interleukin-12 (IL-12) and interleukin-18 (IL-18).
NAMI Mobile
Grant in 2023
NAMI Mobile promotes free mental illness education, support, and advocacy to individuals in need.
CSG Justice Center
Grant in 2023
CSG Justice Center is a non-profit organization that specializes in safety and second chances, along with providing assistance.
American Psychiatric Association
Grant in 2023
The American Psychiatric Association is an organization of psychiatrists that offers diagnosis services and treatment for persons with mental disorders, including intellectual disabilities and substance use disorders. The society’s Diagnostic and Statistical Manual of Mental Disorders (DSM) is the standard classification of mental disorders used by mental health professionals in the United States, which contains a listing of diagnostic criteria for every psychiatric disorder recognized by the U.S. healthcare system. The American Psychiatric Association was founded in 1844 and is based in Virginia, United States.
12-24 Club
Grant in 2023
12-24 Club is a community resource built around recovery from addiction. They strive to provide a safe, anonymous environment to groups and individuals seeking recovery through mutual support.
Ovations for the Cure
Grant in 2023
Ovations for the Cure is to help women who are undergoing treatment for ovarian cancer, as well as to educate them.
She Recovers Foundation
Grant in 2023
She Recovers Foundation is a non-profit organization dedicated to redefining recovery, inspiring hope, eradicating stigma, and empowering women in or seeking recovery to expand their recovery capital, heal themselves, and assist other women in doing the same.
Caregiver Action Network
Grant in 2023
Caregiver Action Network offers education, peer support, and resources to family caregivers across the country.
Foundation for Women's Cancer
Grant in 2023
FWC is a non profit that provides funding for gynecologic cancer research and training, educational programs and resources.
Cancer Legal Care
Grant in 2023
Cancer Legal Care provides compassionate and caring free legal services.
The Recovery Community Network
Grant in 2023
The Recovery Community Network is a non-profit, grassroots Recovery Community Organization dedicated to mobilizing resources inside and outside of the recovery community to enhance the prevalence of and access to substance use disorder recovery.
Ohio Chamber of Commerce Research Foundation
Grant in 2023
Ohio Chamber of Commerce Research Foundation is a non-profit organization focused on delivering research and data that will drive and promote a healthy economy.
American Psychiatric Association Foundation
Grant in 2023
The American Psychiatric Association Foundation, established in 1968, is a non-profit organization based in Washington, D.C. Its primary mission is to promote mental health and well-being among individuals and communities. The Foundation achieves this through various initiatives, including developing and disseminating tools and resources, administering community programs and public education campaigns, and managing grants and awards. It aims to increase mental health literacy, connect individuals to necessary care, and shift societal attitudes towards mental health.
Rodin Therapeutics
Acquisition in 2019
Rodin Therapeutics is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapeutics for cognitive disorders through the application of epigenetic insights. Founded in 2013 with backing from Atlas Venture and Johnson & Johnson Development Corporation, the company leverages advanced structural biology capabilities and a team experienced in central nervous system (CNS) drug development. Rodin's innovative approach centers on the modulation of histone deacetylase (HDAC) complexes to restore synaptic function and promote neuronal health in degenerative brain diseases. This strategy aims to address significant unmet medical needs in the treatment of neurological disorders. As of November 2019, Rodin operates as a subsidiary of Alkermes Inc.
Civitas Therapeutics
Series B in 2013
Civitas Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative pulmonary delivery therapies. Utilizing its proprietary ARCUS technology, the company creates therapeutics aimed at treating central nervous system and respiratory disorders. Civitas Therapeutics serves patients across the United States, focusing on delivering transformative treatment options to improve health outcomes.
Advanced Inhalation Research
Acquisition in 1999
Advanced Inhalation Research is a biotechnology company focused on developing pharmaceutical products utilizing proprietary pulmonary drug delivery technologies. The company specializes in creating dry-powder delivery systems designed for the treatment of respiratory diseases. Additionally, it aims to facilitate the systemic delivery of complex macromolecules through the lungs, leveraging innovative approaches to enhance drug absorption and efficacy.
Enzytech
Acquisition in 1993
Enzytech is a health care company that develops an injectable drug system for multiple sclerosis patients. The company is baed in Cambridge, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.